Clinical trial
A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From a Prograf® Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagraf® Based Immunosuppressive Regimen, Including a Long-Term Follow-Up
NCT01294020 is registered in ClinicalTrials.gov with Astellas Pharma Europe Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From a Prograf® Based Immunosuppressive Regimen to a Tacrolimus Prolonged Release, Advagraf® Based Immunosuppressive Regimen, Including a Long-Term Follow-Up
- Lead sponsor
- Astellas Pharma Europe Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 25, 2011
- Completion date
- November 3, 2025
- Enrollment
- 81 (actual)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.
heart transplantation, intestine transplantation, kidney transplantation, liver transplantation, lung transplantation